Comparison of a loading regimen and a single-dose regimen of intravitreal ranibizumab in the treatment of neovascular age-related macular degeneration

Comparison of a loading regimen and a single-dose regimen of intravitreal ranibizumab in the treatment of neovascular age-related macular degeneration - Necessity of the loading dose of intravitreal ranibizumab for neovascular AMD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006968

Enrollment

Registered

2011-12-28

Start date

2009-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neovascular age-related macular degeneration

Interventions

A single-dose regimen A loading regimen

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: neovascular age-related macular degeneration with best-corrected visual acuity (BCVAs) of 0.15 to 1.30 in the LogMAR unit

Exclusion criteria

Exclusion criteria: previous treatments involving laser photocoagulation, intravitreal triamcinolone, intravitreal bevacizumab, or photodynamic therapy

Design outcomes

Primary

Measure	Time frame
Best-corrected visual acuities (BCVAs)	—

Secondary

Measure	Time frame
Central retinal thickness Averaged injection number of intravitreal ranibizumab	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026